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The Systolic Blood Pressure Intervention Trial (SPRINT) 
Memory and Cognition in Decreased Hypertension (MIND) 
study (1), failed to show a significant effect on the primary 
endpoint (probable dementia, hazard ratio [HR] 0.83; 95% 
CI, 0.67-1.04). Because this may be due to limited power, the 
results of SPRINT MIND were put in the context of major 
randomised and controlled hypertension trials (RCT) in which 
incident dementia had been adjudicated. 
The same search strategy as in an earlier meta-analysis 
(up to 2015) (2) was used to identify trials which fulfilled the 
following criteria: 1) RCT, 2) antihypertensive treatment for at 
least 2 years, 3) dementia (not only cognitive decline or clinical 
impression) as an adjudicated endpoint. Trials not fulfilling 
those criteria were excluded. Seven trials were identified, 
five trials were placebo-controlled, one compared intensive 
vs. usual treatment (1), and in one antihypertensives were 
part of multidomain prevention (3). HRs with 95% CI, and a 
meta-analysis of trials using random effects model and test for 
heterogeneity were performed with NCSS statistical software 8 
(www.ncss.com).
Clinical data and HRs with 95% CI for individual trials are 
shown in Table 1. In addition to total in-trial results, some 
subgroup and extension data, and mild cognitive impairment 
(MCI) for SPRINT MIND are presented.  Except in the Study 
on Cognition and Prognosis in the Elderly (SCOPE) (small 
inter-group blood pressure differences), point estimates of HRs 
for dementia were generally below unity suggesting benefit. 
However, the results were statistically significant only for the 
Systolic Hypertension in Europe (Syst-Eur) trial extension 
and in SPRINT MIND when incident MCI was combined 
with probable dementia (1). When results of the seven trials 
were combined in a meta-analysis (only adjudicated dementia, 
n=1,297), active or a more intensive antihypertensive treatment 
was associated with a significant reduction of dementia by 13% 
(95% CI  -3% to -23%, P=0.011). Although heterogeneity test 
(Cochran’s Q) was nonsignificant (P=0.60), the studies are 
admittedly very different, but this would rather give robustness 
to summary result. The result has also biological plausibility 
from observational studies (2).
To the best of our knowledge, no other intervention has 
similar record of dementia reduction in randomized trials as 
antihypertensive treatment. This message should be actively 
promoted in ageing societies as a feasible, usually safe, 
and with generic drugs also inexpensive way of dementia 
prevention in younger-old people. However, this may not apply 
to frailest and oldest patients (4).
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